%0 Journal Article
%T 维持性腹膜透析患者肾性贫血现状分析及治疗进展<br>Status and Treatment of Renal Anemia in Pa-tients with Maintenance Peritoneal Dialysis
%A 张宏涛
%A 蔄瑜琳
%A 王加如
%A 杨照玉
%A 张静静
%A 籍文捷
%A 杨雨
%A 翟文娟
%A 李欣绪
%A 王志奎
%J Advances in Clinical Medicine
%P 9898-9904
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.12111428
%X 贫血是慢性肾病患者的重要并发症。腹膜透析(peritoneal dialysis, PD)是终末期肾脏病患者最常见的肾脏替代治疗方式之一。在亚太地区尤为普遍，约占总透析人口的2.8%~74.6%。其贫血治疗手段也不断更新，包括新研发的新型低氧诱导因子——脯氨酰羟化酶抑制剂，使用红细胞生成刺激剂、铁剂、输血，我国传统中药制剂也起到了重要作用，未来也可能出现更多纠正贫血的方法供临床医生选择。现就维持性腹膜透析患者肾性贫血治疗方法作一综述，为临床医生提供更多选择。<br />
Anemia is an important complication of chronic kidney disease. Peritoneal dialysis (PD) is one of the most common renal replacement treatments in patients with end-stage renal disease. Peritoneal dialysis is particularly common in the Asia-Pacific region, accounting for 2.8% to 74.6% of the total dialysis population. The treatment methods are also constantly updated, including the newly de-veloped new hypoxia-inducible factor—prolyl hydroxylase inhibitors, the use of erythropoiesis stimulants, iron agents, blood transfusion, and Chinese traditional medicine preparations also play an important role. In the future, there may be more methods to correct anemia for clinicians to choose. This article reviews the treatment methods of renal anemia in patients with maintenance peritoneal dialysis to provide more options for clinicians.
%K 腹膜透析，贫血，治疗<br>Peritoneal Dialysis
%K Anemia
%K Therapeutics
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=57575